Cardioprotection: emerging pharmacotherapy. Expert Opin Pharmacother 2001 May;2(5):739-52
Date
05/05/2001Pubmed ID
11336619DOI
10.1517/14656566.2.5.739Scopus ID
2-s2.0-0034876552 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.
Author List
Gumina RJ, Jahangir A, Gross GJ, Terzic AMESH terms used to index this publication - Major topics in bold
HeartHumans
Ischemic Preconditioning
Magnesium
Myocardial Ischemia
Myocardial Reperfusion Injury
Potassium Channels
Protective Agents
Purinergic P1 Receptor Agonists
Sodium-Hydrogen Exchangers
